OREGON THERAPEUTICS
Oregon Therapeutics is developing XCE853 : disruptive targeted therapy “first in class” and “best in class” in oncology. XCE853 is based on an innovative and unique mechanism of action: inhibition of protein disulfide isomerase. OregonTherapeutics first objective is to bring XCE853 into the clinical phase for the treatment of cancer within 2 years. Based on the scientific rationale to exploit the metabolic vulnerability of some cancers, the two priority indications are ovarian cancer and advanced pancreatic cancer.
OREGON THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2014-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.oregon-therapeutics.com
Total Employee:
1+
Status:
Active
Contact:
+33 0 6 01 03 43 43
Email Addresses:
[email protected]
Total Funding:
0
Similar Organizations
ELARA Pharmaceuticals
ELARA Pharmaceuticals offers research and pharmaceutical development services for new anti-cancer drugs.
Phico Therapeutics
Phico Therapeutics is a developer of novel platform technology designed to overcome antibacterial resistance.
Zhongnong Ying Tailin Prefecture
Zhongnong Ying Tailin Prefecture is a developer of antibacterial peptide.
Investors List
AGORANOV
AGORANOV investment in Venture Round - Oregon Therapeutics
Official Site Inspections
http://www.oregon-therapeutics.com
- Host name: cluster030.hosting.ovh.net
- IP address: 145.239.37.162
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "Oregon Therapeutics"
Oregon Therapeutics – Targeting Cancer with our Onco …
OregonTherapeutics is developing XCE853: Disruptive targeted therapy “First in class” & “Best in class” in oncology.XCE853 is based on an innovative and unique mechanism of action : …See details»
Oregon Therapeutics - Crunchbase Company Profile & Funding
Oregon Therapeutics is developing XCE853 : disruptive targeted therapy “first in class” and “best in class” in oncology. XCE853 is based on an innovative and unique mechanism of action: …See details»
Oregon Therapeutics Company Profile 2024: Valuation, Funding ...
Oregon Therapeutics General Information Description. Developer of new anti-cancer drugs intended to serve the people of France. The company's drugs are created from chemical …See details»
OregonTherapeutics - LinkedIn
OregonTherapeutics is developing XCE853 : Disruptive targeted therapy “First in class” & “Best in class” in oncology. XCE853 is based on an innovative and unique mechanism of action ...See details»
Oregon Therapeutics - Drug pipelines, Patents, Clinical trials
Jul 24, 2024 Explore Oregon Therapeutics with its drug pipeline, therapeutic area, technology platform, 1 news.See details»
OREGONTherapeutics - VentureRadar
To translate this idea into reality, we have combined ground-breaking research with cutting-edge technologies to develop pioneering therapeutics for cancer and beyond. As we prove the value …See details»
Oregon Therapeutics - Funding, Financials, Valuation & Investors
Jan 1, 2015 Oregon Therapeutics is a developer of new anti-cancer drugs. How much funding has this organization raised over time? ShowSee details»
Oregon Therapeutics - Tracxn
Oregon Therapeutics | Founded in the year 2014 · Developer of targeted therapies to treat cancerSee details»
Oregon Therapeutics - Crunchbase
Oregon Therapeutics is a developer of new anti-cancer drugs. Start Free TrialSee details»
Oregon and Lantern collaborate to develop drug candidate for …
May 9, 2024 Oregon Therapeutics and Lantern Pharma have entered into a strategic artificial intelligence (AI)-driven collaboration to optimise the development of a protein disulfide …See details»
Oregon Therapeutics - VentureRadar
Oregon Therapeutics Follow Following " L'objectif du projet OREGON est le développement de nouveaux traitements anticancéreux, en particulier d'un candidat médicament très innovant - …See details»
Oregon Therapeutics & Lantern Pharma Launch Strategic AI …
May 6, 2024 Oregon has developed XCE853 up to regulatory preclinical stage entry and demonstrated XCE853’s disruptive potential as “first in class” and “best in class” candidate in …See details»
Lantern Pharma and Oregon Therapeutics Join Forces to Optimize …
Lantern Pharma Inc. and Oregon Therapeutics have recently announced a strategic collaboration aimed at optimizing the development of XCE853, a promising first-in-class protein disulfide …See details»
Oregon Therapeutics and Lantern Pharma Launch AI Collaboration
May 8, 2024 Lantern Pharma have announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics to optimise the development of its first-in-class …See details»
Lantern Pharma and Oregon partner to develop cancer treatment
May 6, 2024 Oregon will receive financial benefits from the out-licensing of the background IP to Lantern. The companies did not disclose the financial terms of the deal. Oregon Therapeutics …See details»
Oregon Therapeutics - Tech Stack, Apps, Patents & Trademarks
Oregon Therapeutics is a developer of new anti-cancer drugs.See details»
Marc-Henry PITTY - Oregon Therapeutics
Marc-Henry PITTY has successfully created and developed several businesses in the healthcare sector. He graduated as a Medical Doctor from Paris University and also has a specialization …See details»
Oregon Therapeutics - Overview, News & Competitors - ZoomInfo
Oregon Therapeutics. Manufacturing · France · 31 Employees. XCE853 is based on an innovative and unique mechanism of action : Inhibition of protein disulfide isomerase. …See details»
Lantern Pharma partners with Oregon Therapeutics to advance PDI ...
May 7, 2024 Lantern Pharma Inc. has entered into a strategic artificial intelligence (AI)-driven collaboration with Oregon Therapeutics SAS to optimize the development of Oregon’s first-in …See details»
Lantern Pharma and Oregon Therapeutics Join Forces in AI-Driven ...
Jul 10, 2024 Oregon Therapeutics & Lantern Pharma Collaborate to Drive Development of First-In-Class Cancer Drug Candidate XCE853 Using AI TechnologyParis & Dallas - Lantern …See details»